On Thursday, the European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer’s (NYSE: PFE) sickle cell disease drug […]
EU Regulator Recommends Suspension of Pfizer’s Sickle Cell Disease Treatment Read More »
Pfizer’s (NYSE: PFE) decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death
Analysts Say Pfizer’s Oxbryta Exit Could Speed Up Trials for Rival Sickle Cell Drugs Read More »
LONDON – Pfizer (NYSE: PFE) and Moderna’s (NASDAQ: MRNA) legal battle over their rival COVID-19 vaccines will continue after London’s
Pfizer vs. Moderna: COVID Vaccine Patents Battle to Go to Appeal in UK Read More »
On Thursday, the U.S. Food and Drug Administration approved updated COVID-19 vaccines made by Pfizer (NYSE: PFE) and Moderna (NASDAQ:
FDA Greenlights Updated COVID Vaccines to Combat New Variants Ahead of Fall Campaign Read More »
On Monday, Pfizer (NYSE: PFE) said its respiratory syncytial virus (RSV) vaccine Abrysvo generated a strong immune response in a
Pfizer’s (NYSE: PFE) RSV Vaccine Proves Effective for Immuno-Compromised Adults in Study Read More »
Pfizer (NYSE: PFE) raised its annual profit forecast on Tuesday, helped by cancer treatments acquired through a $43 billion deal
Pfizer (NYSE: PFE) Lifts Annual Profit Outlook with Surge in Cancer and Heart Drug Sales Read More »
Pfizer (NYSE: PFE) stock saw a marginal increase in intraday trading Monday following the appointment of a new Chief Strategy
Pfizer (NYSE: PFE) Stock Edges Up After Naming New Chief Strategy Officer Read More »
Pfizer (NYSE: PFE) stock inclined about 2% in intraday trading Thursday after BMO raised its price target. BMO Capital Markets
Pfizer (NYSE: PFE) Stock Gets Boost as BMO Raises Price Target Read More »
Pfizer (NYSE: PFE) stock jumped 6% in intraday trading Wednesday following the release of its first-quarter earnings report. Investors reacted
Copyright © 2025 abbonews.com
